Overview

Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis

Status:
Recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and mortality will measured using the Comprehensive Complication Index (CCI) score, Common terminology criteria for adverse events (CTCAE version 4.03), and the Clavien-Dindo Classification.

Phase:

Phase 2

Details

Lead Sponsor:

University of Kansas Medical Center

Treatments:

Melphalan
Mitomycin
Mitomycins